科伦药业: 关于签订募集资金监管协议的公告

Fundraising Overview - The company issued 30 million convertible bonds at a price of 100 RMB each, raising a total of 3 billion RMB, with a net amount of 2.980054 billion RMB after deducting fees [1][2] - The funds raised are subject to verification by KPMG, which issued a report confirming the amount [1] Fund Usage Changes - The company has terminated the original fundraising projects and redirected the funds towards new projects, including the construction of an intelligent infusion production line and upgrades to existing production lines [1][2] - The company plans to use up to 1.25 billion RMB of idle funds to temporarily supplement working capital, with a repayment period not exceeding 12 months [2] Fund Management and Supervision - The company has established special accounts for the management of the raised funds and signed regulatory agreements with banks and underwriters to ensure proper oversight [2][4] - The supervisory agreements involve multiple parties, including the company, its subsidiaries, and the underwriting institution, ensuring compliance with regulations [4][5] Account Opening and Balance - As of September 4, 2025, the company has opened several special accounts with Bank of China for the management of the raised funds [3][4]